Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Xiaofeng Li; Yueming He; Jinfeng Zhu; Hongxia Pang; Yongwei Lin; Jinyang Zheng

doi:10.18632/oncotarget.25989

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Xiaofeng Li, Yueming He, Jinfeng Zhu, Hongxia Pang, Yongwei Lin and Jinyang Zheng _

PDF | HTML | How to cite

Oncotarget. 2018; 9:33734-33738. https://doi.org/10.18632/oncotarget.25989

Metrics: PDF 1288 views | HTML 4645 views | ?

Abstract

Xiaofeng Li1, Yueming He2, Jinfeng Zhu1, Hongxia Pang1, Yongwei Lin1 and Jinyang Zheng3

1Department of Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China

2Department of Respiratory Diseases, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China

3Department of Pathology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou 362000, China

Correspondence to:

Jinyang Zheng, email: [email protected]

Keywords: angiogenesis; apatinib; sarcomatoid carcinoma; targeted therapy

Received: September 29, 2017 Accepted: March 17, 2018 Published: September 14, 2018

ABSTRACT

Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one case of pulmonary sarcomatoid carcinoma and evaluated the safety and efficacy of apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor 2, in treating this disease. The tumor mass was detected in the left lung of a 75-year-old man and showed positive immunostaining for cytokeratin (CK) 7, CK8, smooth muscle actin, CD31, and CD34. Next-generation sequencing analysis identified 4 mutations in NF1 (p.Q347Sfs^*29), CDKN2A (p.G23V), ERBB3 (p.V104L), and TP53 (p.V157F) genes. The patient was given apatinib (250 mg) orally once per day. Sustained tumor regression was observed after apatinib treatment. There was no sever complication associated with apatinib therapy. In conclusion, apatinib-based targeted therapy may represent an important option for patients with sarcomatoid carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25989

Publication Alerts

Clinical Research Papers:

Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Abstract